Stock Market Reviews

NRIX (Nurix Therapeutics, Inc.) News

Get the latest news, insights, and market updates on NRIX (Nurix Therapeutics, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Incyte (INCY) Soars 5.5%: Is Further Upside Left in the Stock?
  Incyte (INCY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
  Dec 22, 2025 - $NRIX
• Does Strong Early Waldenström Data Redraw The Bull Case For Nurix Therapeutics’ Degrader Platform (NRIX)?
  Nurix Therapeutics recently reported Phase 1 data showing its BTK degrader bexobrutideg (NX-5948) achieved a 75% objective response rate in patients with relapsed or refractory Waldenström macroglobulinemia, with mostly low-grade side effects supporting further development. This early signal suggests Nurix’s targeted protein degradation platform could offer a differentiated approach in a difficult-to-treat blood cancer setting. Next, we’ll explore how this promising Waldenström...
  Dec 22, 2025 - $NRIX
• Wells Fargo Reaffirms a Buy Rating on Nurix Therapeutics (NRIX), Sets a $30 PT
  Nurix Therapeutics, Inc. (NASDAQ:NRIX) is one of the best small cap stocks to buy with huge upside potential. On December 16, Wells Fargo analyst Derek Archila reaffirmed a Buy rating on Nurix Therapeutics, Inc. (NASDAQ:NRIX) with a $30 price target. In a separate development, Nurix Therapeutics, Inc. (NASDAQ:NRIX) announced on December 8 new clinical data […]
  Dec 21, 2025 - $NRIX
• Nurix Therapeutics (NRIX): Revisiting Valuation After a 120% Three-Month Share Price Surge
  Nurix Therapeutics (NRIX) has quietly put together a striking run, with the stock up roughly 120% over the past 3 months even as its 1 year return remains slightly negative, inviting a closer look. See our latest analysis for Nurix Therapeutics. The recent surge looks like a reset in sentiment rather than a one off jump, with a 30 day share price return of 10.5% and a standout 90 day share price return of 119.7%, even as the 1 year total shareholder return remains modestly negative and the 3...
  Dec 21, 2025 - $NRIX
• Nurix (NRIX) Soars 18.7% on Encouraging Blood Cancer Treatment Trial
  We recently published 10 Stocks Standing Tall Amid Market Fall; 6 Hit Record Highs. Nurix Therapeutics Inc. (NASDAQ:NRIX) is one of the best performers on Monday. Nurix Therapeutics extended its winning streak to a fourth straight day on Monday, jumping 18.68 percent to finish at $21.47 apiece as investors took heart from the promising results of […]
  Dec 9, 2025 - $NRIX
• Nurix Therapeutics Presents New Data from the Phase 1 Trial of Bexobrutideg (NX-5948) in Waldenström Macroglobulinemia at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition
  Objective response rate (ORR) of 75.0% including three very good partial responses (VGPR) in heavily pre-treated Waldenström macroglobulinemia patients With a median follow up of 8.1 months, median duration of response (DOR) and median progression-free survival (PFS) have not been reached Encouraging efficacy and favorable tolerability support continued development of bexobrutideg in Waldenström macroglobulinemia Nurix will host a webcast to discuss the data presented at the ASH Annual Meeting a
  Dec 8, 2025 - $NRIX
• Kymera Rockets, Pulling Nurix Higher. Does It Have The Next Dupixent?
  Kymera Therapeutics could have the next Dupixent, analysts said Monday, as shares skyrocketed on promising test results in eczema.
  Dec 8, 2025 - $NRIX
• Nurix Therapeutics Presents New Data Demonstrating Durable, Deepening Responses in Phase 1 Trial of Bexobrutideg (NX-5948) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition
  Objective response rate (ORR) of 83% including two complete responses in CLL patients in Phase 1a study with median progression free survival (PFS) of 22.1 months across all doses tested Emerging data from randomized Phase 1b cohorts points to higher ORR and longer progression free survival at the 600 mg recommended Phase 2 dose (RP2D) compared to the 200 mg dose Bexobrutideg was well tolerated with a consistent safety profile between the 600 mg RP2D and the overall study population Phase 2 clin
  Dec 6, 2025 - $NRIX
• Nurix Therapeutics (NRIX): Assessing Valuation as Investors Await Key NX-5948 Clinical Data Webcast
  Nurix Therapeutics (NRIX) is drawing attention this week as the company prepares to host a webcast to review new and updated clinical data from its ongoing Phase 1a/1b trial of NX-5948 in hard-to-treat blood cancers. See our latest analysis for Nurix Therapeutics. Nurix’s upcoming clinical data webcast comes at a time of renewed investor interest, with the stock seeing a 30.7% gain in its 1-month share price return and a striking 78.8% upside over the past 90 days. Despite this recent...
  Dec 2, 2025 - $NRIX
• Nurix Therapeutics Announces Webcast to Review New and Updated Data from the Phase 1 Clinical Trial of BTK Degrader Bexobrutideg (NX-5948) To Be Presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition
  SAN FRANCISCO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines in oncology and autoimmune diseases, today announced that the company will host a live webcast on Monday, December 8, 2025, at 8:15 p.m. ET, to review new and updated clinical data from the ongoing Phase 1a/1b clinical trial of its Bruton’s tyrosine kinase (BTK) de
  Dec 1, 2025 - $NRIX